The Robot Report

  • Home
  • News
  • Technologies
    • Batteries / Power Supplies
    • Cameras / Imaging / Vision
    • Controllers
    • End Effectors
    • Microprocessors / SoCs
    • Motion Control
    • Sensors
    • Soft Robotics
    • Software / Simulation
  • Development
    • Artificial Intelligence
    • Human Robot Interaction / Haptics
    • Mobility / Navigation
    • Research
  • Robots
    • AGVs
    • AMRs
    • Consumer
    • Collaborative Robots
    • Drones
    • Exoskeletons
    • Industrial
    • Self-Driving Vehicles
    • Unmanned Maritime Systems
  • Markets
    • Agriculture
    • Healthcare
    • Logistics
    • Manufacturing
    • Mining
    • Security
  • Financial
    • Investments
    • Mergers & Acquisitions
    • Earnings
  • Resources
    • Careers
    • COVID-19
    • Digital Issues
    • Publications
      • Collaborative Robotics Trends
      • Robotics Business Review
    • RBR50 Winners 2022
    • Search Robotics Database
    • Videos
    • Webinars / Digital Events
  • Events
    • RoboBusiness
    • Robotics Summit & Expo
    • Healthcare Robotics Engineering Forum
    • DeviceTalks
    • R&D 100
    • Robotics Weeks
  • Podcast
    • Episodes
    • Leave a voicemail

TransEnterix escapes shareholders lawsuit

By Brad Perriello | October 10, 2017

TransEnterixTransEnterix (NYSE:TRXC) last week won the dismissal of a shareholders lawsuit brought over the collapse of its SurgiBot program, with a federal judge ruling that the company and its management and investors didn’t mislead shareholders about the robot-assisted surgery platform’s prospects with the FDA.

The case dates back to the spring of 2016, when Research Triangle Park, N.C.-based TransEnterix’s shares plunged after it revealed that the FDA denied its 510(k) application for SurgiBot, saying that the platform didn’t meet the criteria for substantial equivalence. The company soon shelved SurgiBot and turned to the already-CE-Marked ALF-X device it bought in a $100 million deal with Italy’s Sofar last year.

That prompted two sets of investors to file securities class actions seeking to cover investors who owned TRXC shares between Feb. 10 and May 10 last year. They alleged that TransEnterix and its management “made materially false and misleading statements” about SurgiBot’s prospects with the FDA in press releases, conference calls and SEC filings (the cases were later consolidated before Judge James Dever III of the U.S. District Court for Eastern North Carolina). Specifically, the suits claimed that TransEnterix failed to provide human-factors data to the FDA and kept that knowledge from investors.

“The amended complaint’s allegations do not support this theory,” Dever wrote in an Oct. 6 ruling. “The amended complaint alleges that the FDA’s public forum and guidance expressed the FDA’s expectation that 510(k) applications for products like SurgiBot would contain human-factors data. During SurgiBot’ s review process, the FDA communicated with TransEnterix in a manner consistent with the FDA’s public statements and guidance. The FDA’s request for additional information in August 2015 ‘focused on human factors testing and evaluation,’ and the TransEnterix defendants ‘attempted to satisfy the FDA’s requests concerning human-factors issues.’ The FDA ultimately denied SurgiBot’s 510(k) application because it ‘was insufficient for “substantial equivalence” findings.’ These allegations do not support an inference that SurgiBot’s 510(k) application lacked human-factors data and thus was unlikely to win approval.

“Plaintiffs do not claim that this determination turns solely on the existence or not of sufficient human-factors data. In short, the amended complaint’s allegations do not warrant the inference plaintiffs draw. Plaintiffs have alleged no specific facts to support their assertion that approval of SurgiBot’ s 510(k) application was ‘substantially unlikely’ in light of the fact TransEnterix had not provided human factors data,” he wrote in dismissing the case with prejudice, ordering each side to bear its own legal costs.

“We are pleased that the securities class action suit was dismissed,” TransEnterix president & CEO Todd Pope said in prepared remarks. “We remain confident in achieving FDA 510(k) clearance of the Senhance Surgical Robotic System and continue to focus on transitioning toward U.S. commercialization.”

TRXC shares were up 1.4% to $1.505 apiece today in mid-day trading.

About The Author

Brad Perriello

Brad Perriello has written for The Associated Press, The Eagle-Tribune, Boston.com, The Boston Globe, Industrial Distribution magazine and a variety of local and regional newspapers. He received a master’s degree in journalism from Boston University in 2005. He helped co-found MassDevice and leads WTWH Media’s life science editorial team.

Tell Us What You Think! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Articles Read More >

Ekso Bionics exoskeleton cleared for use with MS patients
moon surgical
Moon Surgical raises $31.3M for robotic surgery system
ElliQ
Intuition Robotics partners with NY State Office for the Aging
Intuitive collaborating with Creo Medical to enhance surgical robots

2021 Robotics Handbook

The Robot Report Listing Database

Latest Robotics News

Robot Report Podcast

Anders Beck introduces the UR20; California bans autonomous tractors
See More >

Sponsored Content

  • Magnetic encoders support the stabilization control of a self-balancing two-wheeled robotic vehicle
  • How to best choose your AGV’s Wheel Drive provider
  • Meet Trey, the autonomous trailer (un)loading forklift
  • Kinova Robotics launches Link 6, the first Canadian industrial collaborative robot
  • Torque sensors help make human/robot collaborations safer for workers

RBR50 Innovation Awards

Leave us a voicemail

The Robot Report
  • Mobile Robot Guide
  • Collaborative Robotics Trends
  • Field Robotics Forum
  • Healthcare Robotics Engineering Forum
  • RoboBusiness Event
  • Robotics Business Review
  • Robotics Summit & Expo
  • About The Robot Report
  • Subscribe
  • Advertising
  • Contact Us

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search The Robot Report

  • Home
  • News
  • Technologies
    • Batteries / Power Supplies
    • Cameras / Imaging / Vision
    • Controllers
    • End Effectors
    • Microprocessors / SoCs
    • Motion Control
    • Sensors
    • Soft Robotics
    • Software / Simulation
  • Development
    • Artificial Intelligence
    • Human Robot Interaction / Haptics
    • Mobility / Navigation
    • Research
  • Robots
    • AGVs
    • AMRs
    • Consumer
    • Collaborative Robots
    • Drones
    • Exoskeletons
    • Industrial
    • Self-Driving Vehicles
    • Unmanned Maritime Systems
  • Markets
    • Agriculture
    • Healthcare
    • Logistics
    • Manufacturing
    • Mining
    • Security
  • Financial
    • Investments
    • Mergers & Acquisitions
    • Earnings
  • Resources
    • Careers
    • COVID-19
    • Digital Issues
    • Publications
      • Collaborative Robotics Trends
      • Robotics Business Review
    • RBR50 Winners 2022
    • Search Robotics Database
    • Videos
    • Webinars / Digital Events
  • Events
    • RoboBusiness
    • Robotics Summit & Expo
    • Healthcare Robotics Engineering Forum
    • DeviceTalks
    • R&D 100
    • Robotics Weeks
  • Podcast
    • Episodes
    • Leave a voicemail